To Pledge or not to Pledge Research Paper Example | Topics and Well Written Essays - 1500 words

To Pledge or not to Pledge - Research Paper Example According to Nelson (2012), the enduring significance of the Nightingale Pledge may be attributed to the legacy of the first nursing icon, Florence Nightingale, in her unwavering dedication to cater the needs of the sick and needy, particularly during difficult times, such as war, famine, disease, and natural calamities (pp. 10-11). Considering the eminent influence of the Nightingale Pledge on a nurse’s life, this paper attempts to uncover the underlying historical significance of the said pledge. Further, this paper also attempts to study the various contexts of the Pledge, especially its functions, purpose, ethical significance, limitations, and criticisms. Historical Role As a profession, nursing is deeply rooted in the society due to its outward protection of the rights of humans, particularly in their rights to life and well-being. In fact, Fagermoen (2005) states that the philosophical foundations of nursing are based on the principles of Humanism wherein nurses, even i n their early not standardized practice, aim to protect, serve, and preserve human life (p. 157). Florence Nightingale embodies those humanistic values in her devotion to tend the wounded soldiers of the Crimean War, and, while alleviating the physical conditions of the soldiers, she also attempts to advance the care systems and psychosocial environment of hospitals so as to make those more conducive to a faster healing process (Fagermoen, 2005, p. 157). During her tenure as a military nurse, she wrote a series of nursing books and notes outlining the basic responsibilities and duties of a nurse, which, in later years, became the theoretical and practical foundations of professional nursing (Kim, 2005, p. 1). The life and works of Florence Nightingale gave birth to the nursing profession, a profession that overcomes barriers of time, place, culture, and religion. For instance, although her works influenced the nursing profession, Florence Nightingale was not the one who wrote the Ni ghtingale Pledge; instead, the pledge was authored by Lystra Gretter, an American nurse (â€Å"The Nightingale Pledge,† n.d.). The pledge was first professed by the 1893 nursing graduates of Detroit’s Harper’s Hospital. Nightingale’s legacy even reached in Japan during the outbreak of the war in 1945 wherein a head nurse in Hiroshima Army Red Cross initiated the recitation of the Nightingale Pledge to restore calm and order in the panic-stricken hospital due to the defeat and surrender of the Japanese militia. Nursing stories around the world relate to the Nightingale Pledge wherein most, if not all, nurses find self-satisfaction in their work through saving the lives of others. Function and Purpose In analyzing the Nightingale Pledge, one can infer that the pledge functions as an ethical guide for nurses in their professional practice while it also aims to indicate the roles, obligations, and limitations of being a nurse. For instance, although the Night ingale Pledge undergoes several legislative revisions and amendments due to socio-cultural concerns, the revised and amended versions of the pledge still maintains the universal nursing standard of conduct, which includes professionalism (â€Å"The Code of Ethics,† 2010, p. xiv). For instance, some of the revisions include the ANA 1950 Code and the 1976 Code; each of which outlines the recommended nurse-patient relationship, which is primarily on a professional level. For instance, the prevailing idea of the revised editions delves on a

Science and future Essay Example for Free

Science and future Essay We have reached upon top of our life by the help of science and technologicalthings. Science and technology has totally revived our life and taught us the way to live our life. Science and technology has not only changed our life but also our physical appearance, character, style, etc. As science and technology has changed step wise, similarly human life has also changed steeply. It can be known by thinking that our primitive used to be toys cnlmpanzee / monkey so tnougnt Dy our ancestors, tnen we developed a little an changed into human being living in Jungle and using leaves ofplantas clothes. At last we became fully matured and emerged as a social being preferring to live in society ather than Jungles. That is one of the great change that science and technology has provided to us. StudyMode. com is the webs Science and technology has also changed our way of living. Theworkhich we leading learning tool. did our selfln past time is being done by machines now-a-days. The We inspire millions of students combination of science and technology has been done to make such robots every day with over 1 which can do home as well as official works.

Cell-based Therapy For Myocardial Regeneration

Cell-based Therapy For Myocardial Regeneration ABSTRACT Myocardial infarction is one of the main cause of mortality in many countries. Therefore, an effective therapy for myocardial infarction is required. Reperfusion and other conventional therapy have been the mainstay therapy for myocardial infarction. However, many patients remain refractory to this therapy. Cell-based therapy is considered a novel therapy, in which stem cells are used for cardiac repair. Stem cells are potential therapeutic and promising option that could be the alternative solution for salvaging damaged cardiomyocyte. Based on current studies, stem cells are a promising therapeutic approach for myocardial infarction. However, some challenges need to be answered by future studies before this novel therapy can be widely applied. This essay provides an overview of the progress in stem cell therapy for myocardial infarction. INTRODUCTION The robust potential of stem cells were still a mystery, but today, we are constantly getting new information on this particular topic. One of the prospects of stem cell therapy is to treat damaged cardiomyocyte (Fischer, et.al, 2009; Beltrami, 2003).Acute myocardial infarction is one of the main causes of mortality and morbidity in many countries. Not only this disease causes a massive socio-economic burden, but also reduces the quality of live for patients who survive the attack (Hamm, 2016). Currently, one of the mainstay therapy for myocardial infarction is rapid revascularization to limit ischaemic damage. Reperfusion and other conventional therapy have undoubtedly saved so many lives, yet there are patients remained refractory to this therapy and left with no other treatment options. In addition to that, many patients who have underwent reperfusion strategy and survived, often left with significant impairment of left ventricular systolic function. One big question remain unansw ered. Is there any other treatment option for these patients? Medical therapeutic approach to reduce damaged cardiomyocyte and generate new functioning muscle is the current unmeet need. Stem cells emerge as the novel procedure to restore damaged cardiomyocytes, and this procedure is popularly known as cellular cardiomyoplasty (Pendyala, et.al, 2008; Reinlib, 2000). Many preclinical and clinical trials have documented the potential use of stem cells to generate viable cardiomyocyte and improve cardiac function (Bergmann, et.al, 2009). To date, there are many different types of adult stem cells and progenitor cells used for this procedure, some of which are bone marrow derived stem cells, hematopoietic stem cells, mesenchymal stem cells and so on. Since the advance of stem cells technology is faster than ever before, this essay aimed to give an evidence based update on stem cells use for myocardial infarction, what we have achieved so far, and what does the future hold for this breakthrough. CELL-BASED THERAPY FOR MYOCARDIAL REGENERATION After an ischaemic attack due to occluded coronary vessels, heart muscle usually left damaged and nonfunctioning. However, recent evidence suggested that the cardiac muscle could actually undergo a limited amount of renewal. A prospect of inducing muscle cell to undergo division for cardiomyocyte replacement, or generating new muscle by stem cells are certainly intriguing (Roell, et.al, 2002; Santoso, et.al, 2011). Stem cells are capable to proliferate in the same state (self-renewal) and differentiate into multiple cell lineages. On the other hand, progenitor cells are more specific and have limited differentiation potential. Mechanism on how stem cells work are as follows: firstly, these stem cells need to be extracted from the source (eg. bone marrow), after that these stem cells need to be delivered to the injured area. These cells are implanted in the myocardium, and due to the nature of these cells, they would grow and differentiate/transdifferentiate into cardiomyocyte. To achieve the goal of cardiac repair, these cells should also have the ability to fuse with the surrounding tissues that their harmonious contraction increases the heart contraction. Furthermore, these newly-formed cardiomyocyte should also express the appropriate electromechanical properties required for contraction to yield a synchronous contraction (Templin, et.al, 2011; Makino, et.al, 1999). Many clinical studies have documented the feasibility and safety of cellular cardiomyoplasty in patients with coronary artery disease (Makino, et.al, 1999; Strauer, et.al, 2002). To date, there are some different types of adult stem cells and progenitor cells used for this procedure, some of which are bone marrow derived stem cells, hematopoietic stem cells, mesenchymal stem cells and many others (Jackson, et.al, et.al, 2001; Kamihata, et.al, 2001; Bolli, et.al, 2011) POTENTIAL SOURCE AND TYPE OF STEM CELLS Bone Marrow Derived Stem Cells Bone marrow derived stem cells (BMCs) are the most widely studied type of stem cells. Orlic et al. (2001) first describe the ability of bone marrow cells to regenerate infarcted myocardium in mouse models. The transplanted cells showed transdifferentiation into cardiomyocyte which eventually lead to improved left ventricular ejection fraction (Orlic, 2001). The three types of stem cells derived from bone marrow are hematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs), and endothelial progenitor cells (EPCs) (Orlic, 2001; Piao, et.al, 2005; Badorff, et.al, 2003). The role of BMCs for acute myocardial infacrtion has been reported to improve left ventricular ejection fraction (LVEF), both in REPAIR-AMI and BOOST trial (Meyer, et.al, 2006; Schachinger, et.al, 2006).BOOST trial demonstrate an acceleration of LVEF after intracoronary BMCs transfer (ejection fraction increased by 6.7% in the BMCs group as compared to 0.7% in the control group), and significant result was sustained until 18 months (Meyer, et.al, 2006). While in REPAIR AMI trial, improvement of LVEF, infarct size and wall thickening of infarcted segments were reported at two years follow up. At two years, the cumulative end point of death, myocardial infarction, or necessity for revascularization was significantly reduced in the BMC group compared with placebo (hazard ratio, 0.58; 95% CI, 0.36 to 0.94; P=0.025) (Assmus, et.al, 2010; Perin, et.al, 2012). Skeletal Myoblast Skeletal muscle has the ability to regenerate under certain circumstances. Skeletal resident stem cells are usually known as satellite cells, and these cells would differentiate to new myocytes in response to injury. However, whether this ability can be translated to a different condition, as in cardiomyocyte repair, should be further studied (Taylor, 198; Reinecke, et.al, 2002). MAGIC trial, a randomized controlled phase II trial, showed no significant changes in terms of global and regional LV function in skeletal myoblast- treated patients (Mensche, et.al, 2008). Another study performed by Dib et al.(2005) showed an increased in LV ejection fraction in the group treated with transepicardial injection of autologous SMs. Mesenchymal Stem Cells Mesenchymal stem cells (MSCs) are another potential option for cellular cardiomyoplasty. Mesenchymal stem cells can be found in various tissue, such as bone marrow and adipose tissue (Pittenger, 2004). One interesting mechanism by which MSCs mediate cardiac function improvement is the paracrine effect. MSCs may secrete soluble cytokines and growth factors that would eventually influence adjacent cardiomyocyte (Gharaibeh, et.al, 2011). Hare JM et al. (2009) studied the efficacy of intravenous allogenic human mesenchymal stem cells in patients with myocardial infarction. According to this study, intravenous MSCs were safe as showed by the similar adverse event rates in both intervention and control group. MSCs injection favorably affected patient functional capacity, quality of life and LV remodeling (Hare, et.al, 2012). Endothelial Progenitor Cells Endothelial progenitor cells (EPCs) have been linked with neovascularization in ischemic tissue. This interesting finding lead to the use of EPCs for another therapeutic purpose like cellular cardiomyoplasty (Isner, et.al, 1999). The human peripheral blood-derived EPCs would be a potential approach because those cells can be easily isolated without the need of major surgical intervention (Lin, et. Al, 2000). This assumption was later confirmed by Badorff et al. In this study, Badorff et al. (2003) reported that EPCs from healthy volunteers and Coronary Artery Disease (CAD) patients can transdifferentiate into functionally active cardiomyocytes when co-cultivated with rat cardiomyocytes. However, this finding was later opposed by Gruh I et al. According to this study, there was no significant evidence of transdifferentiation of human EPCs into cardiomyocyte (Gruh, et.al, 2006). Resident Cardiac Stem Cells Until recently, we believe that heart is a fully mature organ with no capability of self-renewal. However, the adult heart is not a terminally   differentiated organ, but harbors stem cell with regenerative capacity, namely resident cardiac stem cells (CSCs). Although the origins of CSCs are yet unclear, they can be isolated from heart tissue and expanded ex vivo for use as a cell-based therapy. There were many types of CSCs have been described in previous studies, like: epicardium-derived cells, cardiosphere-derived cardiac cells, and cardiac Sca-1+ cells. These resident stem cells have the potential to differentiate into different types of cells like vascular smooth muscle and myocardial cells (Tang, et.al, 2013; Tang, et.al, 2006; Fazel, et.al, 2006). Embryonic Stem Cells and Induced Pluripotent Stem Cells (iPS) Embryonic stem cells (ESC) are derived from the blastocyst (inner cell mass) of human embryo prior to implantation. ESCs are pluripotent cells, which means they have the capability to differentiate into any cells, one of which is cardiac myocytes. Due to the source of these cells, there are ethical issues regarding the use of ESC (Kofidis, 2005).The huge potential of ESC comes with a price. The pluripotency of ESC made these cells predisposes to tumor formation including teratomas. Amariglio N et al. (2009) documented the occurence of a human brain tumour following neural stem cell therapy. A boy with telangiectasia was treated with intracerebellar and intrathecal injection of human fetal neural stem cells. Four years later, he was diagnosed with a multifocal brain tumour. After thorough analysis, the tumor was of nonhost origin, indicating it was derived from the transplanted neural stem cells (Amariglio, 2009). To date, due to the scarcity of studies on ESC and negative experiences of previous studies, the significance of ESC as cell-based therapy for myocardial infaction remains elusive. The above-mentioned limitation would hopefully be elucidated in future research. Human Umbilical Cord Blood Cells Human umbilical blood cells (hUCB) contains a large number of non-hematopoietic stem cells which rarely express human leukocyte antigen (HLA) class II antigens, thus reducing the risk of rejection. Many studies have reported the efficacy and safety of hUCB administration in acute myocardial infarction model, with conflicting result (Henning, 2004; Moelker, 2007).According to Henning RJ et al. (2004) hUCB administration reduce infarction size and improve ventricular function in rats without requirements for immunosuppression (Henning, 2004). Similar positive finding were documented by Kim et al. Circulating Blood-derived Progenitor cells Circulating blood-derived progenitor cells (CPCs) are similar to BMCs, which mainly composed of EPCs. Santoso T et al. (2011) studied the safety and feasibility of combined granulocyte colony stimulating factor (G-CSF) and erythropoetin (EPO) based-stem cell therapy using intracoronary infusion of peripheral blood stem cells in patients with recent anterior myocardial infarction. G-CSF is used to mobilized stem cells to the injured area, inhibits cardiomyocyte apoptosis, promotes neovascularization, and increase the production of nitric oxide. While EPO, that is originally thought to be a hematopoietic hormone only, also may inhibited apoptosis and induced angiogenesis. This phase I study concluded that this procedure is safe and resulted in improved endpoints for LV ejection fraction and cardiac viability (Santoso, 2011). Cardiopoietic Stem Cells Cardiopoietic stem cells are not a distinct type of stem cells but refer to the novel way of processing stem cells in order to get a lineage specification. Cardiopoietic stem cells are harvested stem cells that are treated with a protein cocktail to replicate natural cues to heart development, before being injected into the patients heart. The C-CURE trial studied the efficacy of bone marrow derived-mesenchymal stem cells in chronic heart failure. The isolated mesenchymal stem cells were exposed to a cardiogenic cocktail that trigger expression and nuclear translocation of cardiac transcription factors, before being injected to the patients heart. After six months follow up, patients in the treatment group significantly improved in terms of LVEF and fitness capacity. There was no evidence of increased cardiac or systemic toxicity induced by cardiopoietic cell therapy (Bartunek, 2013). Unfortunately, data comparing the efficacy and safety between cardiopoietic stem cells and ordinary stem cells without cocktail-based priming is still lacking. DELIVERY METHODS In order to make these stem cells reach the heart, a reliable delivery method need to be employed. The ideal method should be able to safely and efficiently deliver an optimal number of stem cells to the target tissue. Beside the high efficacy, this delivery method should be as minimally invasive as possible for the sake of patients comfort. There are some delivery methods worthy to know. Intracoronary Infusion As the name implies, intracoronary infusion is a process of delivering stem cells through coronary artery, usually through intracoronary catheterization. Stem cells are infused under pressure via a ballon catheter. The ballon was inflated in order to prevent anterogade blood flow that would compromize stem cells delivery. Catheter guided cell transfer has its unique advantage of safety under local anesthesia, and a part of routine cardiac catheterization. The intracoronary method provide a maximum number of cells to the target area, with good blood supply which is crucial for cell survival. Multiple studies have reported the use of intracoronary infusion for stem cells delivery (Strauer, 2002; Schachinger, 2006). Intravenous Peripheral Infusion Intravenous stem cells administration is one of the easiest method to be employed. Intravenous administration is possible through homing phenomenon of stem cells to the injured heart. Unfortunately, intravenous peripheral infusion comes with some disadvantages. First, only 3% of normal cardiac output will flow per minute through the left ventricle. This low amount of blood would limit the amount of stem cells delivered. Secondly, due to the passing of venous blood in the lung, many cells would trap in lung vasculature that eventually lead to stem cells reduction (Grieve et.al, 2012). Intramyocardial, Transendoccardial and Transpericardial Route As mentioned earlier, the downside of intravenous administration is the passing of the blood in certain organs that would entraped some of the stem cells. Unlike intravenous route, intramyocardial method is undoubtly provide direct access to the injured cardiomyocyte bypassing the need for mobilization, homing and any risk of cells entrapment in other organ, thus provide a more effective way to deliver abundant stem cells to the injured area. However, this method comes with its own expense of a more invasive method, not to mention the risk of ventricular perforation in the already damaged cardiomyocyte. Intramyocardial delivery usually performed during an open heart surgery or needle-tipped delivery catheter (Strauer, 2003; Forrester, 2003). Nelson et al.(2009) documented that intamyocardial delivery of iPS originating from reprogrammed fiobroblast, yielded progeny that properly engrafted and resulted in restored contractile performance, increased ventricular wall thickness, and elec tric stability (Nelson, et.al, 2009). STUDIES USING STEM CELLS IN MYOCARDIAL INFARCTION Many studies have been carried out to investigate the efficacy and safety of stem cell therapy in patients with myocardial infarction. Each of these studies investigated different kind of stem cells with different delivery methods. The ultimate goal of these studies is to answer whether stem cell therapy could be a feasible therapeutic approach for patients with myocardial infarction. The result of these studies were not always positive, even some of the studies did not document any beneficial effect of stem cell therapy. However, this conflicting result need to be intepreted with caution due to the different study method, different type of stem cells used, and different delivery methods employed. Three meta- analysis on the efficacy of BMCs therapy for myocardial infarction have been published. In a meta-analysis by Delewi R et al, intracoronary BMCs infusion is associated with improvement of LV function and remodelling in patients after ST-segment elevation myocardial infarction. The benefit in terms of LVEF improvement was more pronounced in patients with a worse baseline LVEF (LVEF cut off: 40%) and younger age (age cut off: 55 years) (Delewi, et.al, 2013).   In a second meta-analysis by Clifford DM et al. (2012) which include thirty-three RCTs, there was no significant difference in hard end point like mortality and morbidity in the BMCs treated group. However global heart function, as represented by LVEF and infarct size, was improved significantly and was sustained long term (12 to 61 months) in the BMCs group (Clifford, et.al, 2012). The third meta-analysis by Long C et al. (2013) further confirmed the beneficial effect of intracoronary BMCs in patients with acute my ocardial infraction. According to this meta-analysis, BMCs therapy significantly improved LVEF, while mildly but not significantly reduced left ventricular end-systolic volume and left ventricular end-diastolic volume (Lond, et.al, 2013). These three meta-analysis synonymously agree that BMCs therapy is beneficial in terms of improved heart function and reduced infarct size. CHALLENGES AND THE FUTURE We have just entered the new era of stem cell therapy. When advanced therapy like primary PCI and thrombolytic showed more limited beneficial for patients with myocardial infarction, the concept of cell-based therapy is definitely appealing. This new approach could be the answer that have been waited for sometime. As we have discussed previously, there are many issues on stem cell therapy that need to be addressed in future studies. Firstly, what is considered to be the best stem cells to replace cardiomyocyte. Secondly, the right delivery method of these stem cells need to be determined. Whether different type of stem cells required certain delivery methods also need to be further elucidated. Another question is the right timing of delivery (acute, sub-acute or chronic), whether it contributes to the fate of stem cells. Fourth, the concentration of stem cells, dose-effect relationship and safety of stem cell therapy need to be further investigated. One particular topic in regard to stem cell safety is the tumorigenicity of ESC. We need to disentangle a way to reprogram these cells so they can differentiate into functional cells, but lack the ability to form tumours. Finally, novel diagnostic tools are required to detect and evaluate stem cells therapy. Future studies would hopefully provide s olid proof on hard end-points (eg. mortality), instead of surrogate markers like LVEF or infarct size. CONCLUSION Tremendous progresses were made in cell-based therapy, and future advances would further lead us to a new solution for ischaemic heart disease. Stem cells own robust potential in medicine, one of which is to replace damaged cardiomyocyte. More evidents are needed in advance to widely use of this modality. REFERENCES Amariglio N, Hirshberg A, Scheithauer BW, et al. (2009). Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. Assmus B, Rolf A, Erbs S, et al. (2010). Clinical outcome 2 years after intracoronary administration of bone marrow-derived progenitor cells in acute myocardial infarction. Circ Heart Fail, 3, pp.89-96. Assmus B, Schachinger V, Teupe C, et al. (2002) Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation. 106, pp.3009-3017. Badorff C, Brandes RP, Rà ¼diger P, et al. (2003). Transdifferentiation of blood-derived human adult endothelial progenitor cells into functionally active cardiomyocytes. Circulation. 107, pp.1024-32. Beltrami AP, Barlucchi L, Torella D, et al. (2003) Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell, 114(6), pp.763-776. Bergmann O, Bhardwaj RD, Bernard S, et al. (2009). Evidence for cardiomyocyte renewal in humans. Science. 324, pp. 98-102. Bolli R, Chugh AR, DAmario A, et al. (2011). Effect of cardiac stem cells in patients with ischemic cardiomyopathy: Initial results of the SCIPIO trial. Lancet, 378, pp. 1847-1857. Cao F, Sun D, Li C, et al. (2009). Long-term myocardial functional improvement after autologous bone marrow mononuclear cells transplantation in patients with ST-segment elevation myocardial infarction: 4 years follow-up. Eur Heart J, 30, pp.1986-94. Chang ZT, Hong L, Wang H, Lai HL, Li LF, Yin QL. (2013). Application of peripheral-blood-derived endothelial progenitor cell for treating ischemia-reperfusion injury and infarction: a preclinical study in rat models. J Cardio Thor Surgery. 8, pp.33. Clifford DM, Fisher SA, Brunskill SJ, et al. (2012) Stem cell treatment for acute myocardial infarction. Cochrane database of systematic reviews. Issue 2. Art. No.: CD006536. Doi : 10.1002/14651858.CD006536.pub3. Delewi R, Hirsch A, Tijssen JG, et al. (2013). Impact of intracoronary bone marrow cell therapy on left ventricular function in the setting of ST-segment elevation myocardial infarction: a collaborative meta-analysis. Eur Heart J, doi:10.1093/eurheartj/ eht372. Dib N, Michler RE, Pagani FD, et al. (2005). Safety and feasibility of autologous myoblast transplantation in patients with ischemic cardiomyopathy: four-year follow-up. Circulation. 112, pp.1748-55. Duckers HJ, Houtgraaf J, Van Geuns RJ, et al. (2010). Abstract 12225: First-in-man experience with intracoronary infusion of adipose-derived regenerative cells in the treatment of patients with ST-elevation myocardial infarction: The apollo trial. Circulation, 122, A12225. Fazel S, Cimini M, Chen L, et al. (2006). Cardioprotective c-kit + cells are from the bone marrow and regulate the myocardial balance of angiogenic cytokines. J Clin Invest, 116, pp. 1865-1877. Fernandes S, Amirault JC, Lande G, et al. (2006). Autologous myoblast transplantation after myocardial infarction increases the inducibility of ventricular arrhythmias. Cardiovasc Res, 69, pp.348-358. Fischer KM, Cottage CT, Wu W, et al. (2009). Enhancement of myocardial regeneration through genetic engineering of cardiac progenitor cells expressing Pim-1 kinase. Circulation, 120(21), pp.2077- 2087. Fischer UM, Harting MT, Jimenez F, et al. (2009). Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells Dev, 18, pp.683-692. Forrester JS, Price MJ, Makkar RR. (2003). Stem cell repair of infarcted myocardium: an overview for clinicians. Circulation, 108, pp.1139-1145. Gharaibeh B, Lavasani M, Cummins JH, Huard J. (2011). Terminal differentiation is not a major determinant for the success of stem cell therapy cross-talk between muscle-derived stem cells and host cells. Stem Cell Res The, 2, pp.31. Gimble JM, Katz AJ, Bunnell BA. (2007). Adipose-derived stem cells for regerative medicine. Circ Res, 100, pp.1249-60. Grieve SM, Bhindi R, Seow J, et al. (2012). Microvascular obstruction by intracoronary delivery of mesenchymal stem cells and quantification of resulting myocardial infarction by cardiac magnetic resonance. Circ Heart Fail, 3, pp.e5-e6. Gruh I, Beilner J, Blomer U, et al. (2006). No evidence of transdifferentiation of human endothelial progenitor cells into cardiomyocytes after coculture with neonatal rat cardiomyocytes. Circulation, 113, pp.1326-1334. Hamm CW, Bassand JP, Agewall S, et al. (2016). ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal doi:10.1093/eurheartj/ehr236. Cited from: http://www. escardio.org/guidelines-surveys/esc-guidelines/Pages/ ACS-non-ST-segment-elevation.aspx Hare JM, Fishman JE, Gerstenblith G, et al. (2012). Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy the POSEIDON randomized trial. JAMA. 308, pp.2369-2379. Hare JM, Traverse JH, Henry TD, et al. (2009). A randomized, double-blind, placebo controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol, 54, pp.2277-2286. Henning RJ, Abu-Ali H, Balis JU, Morgan MB, Wiling AE, Sanberg PR. (2004). Human umbilical cord blood mononuclear cells for the treatment of acute myocardial infarction. Cell Transplant. 13, pp.729-739. Hsieh PCH, Segers VFM, Davis ME, et al. (2007).   Evidence from a genetic fate-mapping study that stem cells refresh adult mammalian cardiomyocytes after injury. Nat Med, 13, pp.970-974. Isner JM, Asahara T. (1999). Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J Clin Invest, 103, pp.1231-1236. Jackson KA, Majka SM, Wang H, et al. (2001). Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. J Clin Invest, 107, pp.1395-1402. Kamihata H, Matsubara H, Nishiue T, et al. (2001). Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines. Circulation, 104, pp.1046-1052. Kim BO, Tian H, Prasongsukarn K, et al. (2005). Cell transplantation improves ventricular function after a myocardial infarction: a preclinical study of human unrestricted somatic stem cells in a porcine model. Circulation. 112, pp.I96-I104. Kofidis T, de Bruin JL, Yamane T, et al. (2005). Stimulation of paracrine pathways with growth factors enhances embryonic stem cell engraftment and host-specific differentiation in the heart after ischemic myocardial injury. Circulation, 111, pp. 2486-2493. Kornowski R, Fuchs S, Leon MB, et al. (2000). Delivery strategies to achieve therapeutic myocardial angiogenesis. Circulation, 101, pp.454-458. Krishna KA, Krishna KS, Berrocal R, Rao KS, Rao KRS. (2011). Myocardial inraction and stem cells. J Pharm Bioallied Sci, 3, pp.182. Lin Y, Weisdorf DJ, Solovey A, Hebbel RP. (2000). Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest, 105, pp.71-77. Long C, Yi TJ, Hui J, et al. (1999). Long-term effects of bone marrow-derived cells transplantation in patients with acute myocardial infarction: a meta-analysis. Chin Med J, 126, pp.353-360. Makino S, Fukuda K, Miyoshi S, et al. (1999). Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest, 103, pp.697-705. Makkar RR, Smith RR, Cheng K, et al. (2012). Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet, 379, pp.895-904. Menasche P, Alfieri O, Janssens S, et al. (2008). The myoblast autologous grafting in ischemic cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation. Circulation. 117, pp.1189-1200. Menasche P, Hagege AA, Vilquin JT, et al. (2003). Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. J Am Coll Cardiol, 41, pp.1078-1083. Meyer GP, Wollert KC, Lotz J, et al. (2006).   Intracoconary bone marrow cell transfer after myocardial infraction: eighteen months follow up data from the randomized, controlled BOOST (bone marrow transfer to enhance ST-elevation infarct regeneration) trial. Circulation, 113, pp.1287-1294. Moelker AD, Baks T, Wever KM, et al. (2007). Intracoronary delivery of umbilical cord blood derived unrestricted somatic stem cells is not suitable to improve LV function after myocardial infarction in swine. J Mol Cell Cardiol, 42, pp.735-745. Nelson TJ, Martinez-Fernandez A, Yamada S, Perez-Terzic C, Ikeda Y, Terzic A. (2009). Repair of acute myocardial infarction by human stemness factors induced pluripotent stem cells. Circulation, 120, pp.408-416. Oh H, Bradfute SB, Gallardo TD, et al. (2003). Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction. Proc Natl Acad Sci USA, 100, pp.12313-12318. Orlic D, Kajstura J, Chimenti S, et al. (2001).   Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci USA, 98, pp.10344-10349. Pendyala L, Goodchild T, Gadesam RR, Chen J, Robinson K. (2008). Cellular cardiomyoplasty and cardiac regeneration. Curr Cardiol Rev, 4, pp.72-80. Perin EC, Wilerson JT, Pepine CJ, et al. (2012). Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure the FOCUS-CCTRN Trial. JAMA, 307, pp.1717-1726. Piao H, Youn TJ, Kwon JS, et al. (2005). Effects of bone marrow derived mesenchymal stem cells transplantation in acutely infarcting myocardium. Eur J Heart Fail, 7, pp.730-738. Pittenger MF, Martin BJ. (2004). Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res, 95, pp.9-20. Povsic TJ, OConnor CM, Henry T, et al. (2011). A double-blind, randomized, controlled, multicenter study to assess the safety and cardiovascular effects of skeletal myoblast implantation by catheter delivery in patients with chronic heart failure after myocardial infarction. Am heart J, 162, pp.654-662. Ramshorst JV, Antoni L, Beeres SLMA, et al. (2011). Intramyocardial bone marrow-derived mononuclear cell injection for chronic myocardial ischemia, the effect on diastolic function. Circ Cardiovasc Imaging, 4, pp.122-129. Reejhsinghani R, Jen Shih HH, Lotfi AS. (2012). Stem cell therapy in acute myocardial infacryion. J Clin Exp Cardiolog, 8, pp.11. Reinecke H, MacDonald GH, Hauschka SD, Murry CE. (2000). Electromechanical coupling between skeletal and cardiac muscle. Implications for infarct repair. J Cell Biol, 149, pp.731-740. Reinecke H, Poppa V, Murry CE. (2002). Skeletal muscle stem cells do not transdifferentiate into cardiomyocytes after cardiac grafting

Religion vs. Rights: Which One Belongs In Schools? :: essays research papers

Religion vs. Rights: Which One Belongs In Schools? Before the government provided formal schools and programs of education, religion had been a major part of every person's education. As public schools started, this teaching of faiths continued with the practice of prayer before class and bible reading sessions (Burstein, 26). Were those actions taken in these classes constitutional, or did the practicing of religious activities deny people the freedom of religion guaranteed in the constitution? Many of those who find prayer and religion in school offensive say that it is a violation of their rights. Mr. Justice Black of the United States Supreme Court, once said, "The First Amendment has erected a wall between the Church and State which must be keep high and impregnable" (Bosmajian, 7). Those in support of religious teachings in public schools see participation in theological activities as a chance to teach morals, community ethics, and peace over violence. Nevertheless, the achievement of those goals through the deni al of basic rights is wrong. Today's society is, fast paced, competitive, and based totally on equality. Consequently, religion, whether it be denominational or not, has no place in the classrooms of today's public schools. The reasons for this position are the establishment clause, the rulings of the Supreme Court, and the role that a school has in a community. What is stopping this process of allowing prayer and schools to combine? The establishment clause is the main cause of this roadblock. The American public seems to think that the establishment clause, or religious freedom, means that personal beliefs can be instituted any place at any time. They feel that the courts interpretation of the clause not only takes God out of the lives of the students, but that the removal of religion also removes basic ethics and the teaching of morals (Gay, 65). This removal of ethics seems to have possibly caused the lack of respect for teachers and education as a whole. The courts say that this right's purpose is to create a wall that will separate the church from the state and that it will not and can not fall. This clause is the rock, on which they base all their decisions on, where they turn to figure out whether a violation of rights had occurred. To put this idea into more simple terms, the purpose of the anti-prayer position is that the gove rnment does not want to specifically support, show preference of, or exclude and particular religion or denominational sect (Burstein, 28).

The Importance of Setting

The path to becoming an adult is lined with a variety of childhood and adolescent experiences, some more painful than others. In T. Coraghessen Boyle’s short story, â€Å"Greasy Lake,† Boyle masterfully uses the setting and the protagonist’s experience to teach us an old but vital lesson: those who choose not to learn and grow from their past mistakes are destined to repeat them, and thus will never mature and realize their true potential.At the beginning of the story, the main character (who also happens to be the narrator) depicts his adolescence as â€Å"a time when courtesy†¦went out of style, when it was good to be bad, when you cultivated decadence like a taste† (621). The three thought of themselves as dangerous characters, riding around town wreaking havoc. However, it seems unclear to the main character and his two friends that in reality, they are not actually bad characters. Really bad characters don’t drive their â€Å"parents†™ whining station wagons† (621) or read intellectual French novels by Andre Gide.Boyle gives us a general thought that these three boys are just your ordinary, everyday, misguided juvenile delinquents with an unclear view of what it really means to be a man. Later in the story, the narrator depicts a scene at the main setting of â€Å"Greasy Lake. † There, the three boys provoke who is described as the â€Å"very bad character† (623). The events that took place led the three to realize the ugly truth: they are nothing more than just three kids on an adventure for the night; little did they know what was in store for them.After a lengthy description of the fight that took place between the four characters, the three boys find themselves attempting to rape the girl that was accompanying the â€Å"very bad character. † Luckily, before they can go any farther, another vehicle pulls into the scene, scaring the boys as the flee away. They all run in different directions, leaving them all separated from each other. The main character, with no place else to hide, plunges into the greasy lake.The water is completely contaminated; â€Å"it was fetid and murky, the mud banks glittering with broken glass and strewn with beer cans and the charred remains of bonfires† (622). The setting of â€Å"Greasy Lake† contributes to the plot in a sense of the troubles of the three teenage boys. Much of the story takes place at Greasy Lake, which is not an ordinary, everyday, swimming with the family type of lake. There are crowded trees, which draws a picture of a dark forest with very little light seeping through. The island in the middle of the lake has little or no vegetation, giving the reader a feeling of death.It is also littered with things such as beer cans, broken glass, and bonfire remains. These are items that make you think of loss of control, violence, or even destruction. These ideas could surely lead to something bad happening . The water itself is described as â€Å"fetid and murky† (622). There are two different aspects of time to consider when looking at â€Å"Greasy Lake. † First of all, there is the fact that it is 2 a. m. The middle of the night is commonly a time of day when bad things occur. It is probably considered that the good, peaceful people are at home in bed.Therefore, if someone is up and about they are most likely wreaking havoc. Secondly, there is the year that the story takes place. It was written in the eighties, and it takes place in a time when â€Å"it was good to be bad† (621). Therefore, it is likely that something bad is sure to occur. The setting also serves a very important purpose to most stories by evoking a certain atmosphere. Work Cited Boyle, T. Coraghessan. â€Å"Greasy Lake. † 621 Kirszner, Laurie G. , and Stephen R. Mandell, eds. Literature: Reading, Writing. 8th ed. Boston: Wadsworth, 2013 Print.

Buddhist Monk in Letter Form essays

Buddhist Monk in Letter Form essays Growing up I was very poor and unhappy. I decided very young that the only way to truly understand happiness was to become wealthy. At the age of 12, I went out and got a job as an assistant for a scientist. However, I wanted to make a lot of money. Therefore I chose to work for an evil, rich man. His unethical line of work consisted of terrible studies done on people with physical and mental handicaps. Whenever I would help him with the unethical part of his studies, something bad always happened to my family or me. After multiple mysterious accidents causing death to my family and plenty of injuries to me, I realized money didnt make me happy. I wanted out of the business once I made a connection between my work and my bad luck. I realized I needed change in my life. So I went out and sought knowledge, as you are now. I discovered Buddhism. This is what I found and I hope it will help you. The reason bad things are happening to you and your family/friends is simple. Its called Karma and means the law of moral cause and effect. It includes past and present actions and good or bad karma results from our own actions. Meaning that every time you off someone this is seen as a bad thing and you must receive the bad effects of this. You need to change your life and your occupation. You cannot kill and not expect consequences. Buddhism teaches that the law of karma and the four noble truths, basics of the Buddhas teaching, will help end your suffering. Here are the four noble truths. First, no one can deny that suffering is the conditions of all existence. Buddha understands that everyone suffers. However, he believes that you can end this suffering. The explained reason for this suffering is the second noble truth that general dissatisfaction comes to human beings because they are possessive, greedy! ...